Background. Our aim was to evaluate the quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. We also conducted an analysis of all patients who underwent CRS and HIPEC for pseudomyxoma peritonei from 1997 to 2012. Methods. We contacted 87 patients using the FACT C (version 4) quality of life questionnaire, and FACIT-TS-G (version 1) was also used. Results. A total of 63 patients (response rate 72%) were available for quality of life interview and analysis. The median time from surgery to questionnaire evaluation was 31 months (range 6–161 months). 62% were females with an average age of 54 years. 22% of the patients had over one cytoreductive surgical procedure. We analysed our patients postoperatively based on physical, functional, social, and emotional well being who reported favourable outcomes in all sections. Patients who had a single procedure had a significantly higher score ( ) in the additional concerns section of the questionnaire. The patients who had a single procedure had better gastrointestinal digestion in terms of bowel control, appetite, and food digestion and also body appearance scoring. Conclusions. 79% of the patients stated that they would undergo further cytoreductive surgery and that redo procedures do not result in a significantly worse quality of life. 1. Introduction As a result of pioneering work by Sugarbaker, cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become the mainstay of treatment for pseudomyxoma peritonei (PMP) [1]. Appendiceal neoplasms are uncommon making up 1% of colorectal malignancies [2]. Epithelial appendiceal neoplasms frequently present with mucinous ascites and tumour implants throughout the abdomen. Most cases of PMP result from rupture of a low grade appendiceal tumour with mucin accumulating in the abdominal cavity due to its production by epithelial cells. PMP results in death via obliteration of the peritoneal cavity even though there are little haematogenous or lymph node metastases. In the past, PMP was attempted to be treated with repeated debulking procedures; however, this resulted in recurrence and death secondary to bowel obstruction, surgical complications, or terminal starvation [3]. The macroscopic disease of PMP is targeted by surgical cytoreduction and the microscopic by intraperitoneal chemotherapy. It is a curative treatment option with many centres publishing successful data [4–9]. A major past criticism of cytoreductive surgery has been the associated morbidity and mortality. The only effective
References
[1]
P. H. Sugarbaker, “Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome,” European Journal of Surgical Oncology, vol. 27, no. 3, pp. 239–243, 2001.
[2]
P. H. Sugarbaker, “New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?” Lancet Oncology, vol. 7, no. 1, pp. 69–76, 2006.
[3]
K. E. Bevan, F. Mohamed, and B. J. Moran, “Pseudomyxoma peritonei,” World Journal of Gastrointestinal Oncology, vol. 2, no. 1, pp. 44–50, 2010.
[4]
R. M. Smeenk, V. J. Verwaal, N. Antonini, and F. A. N. Zoetmulder, “Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,” Annals of Surgery, vol. 245, no. 1, pp. 104–109, 2007.
[5]
M. Deraco, D. Baratti, M. G. Inglese et al., “Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei,” Annals of Surgical Oncology, vol. 11, no. 4, pp. 393–398, 2004.
[6]
Z. Güner, U. Schmidt, M. H. Dahlke, H. J. Schlitt, J. Klempnauer, and P. Piso, “Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei,” International Journal of Colorectal Disease, vol. 20, no. 2, pp. 155–160, 2005.
[7]
B. L. Van Leeuwen, W. Graf, L. Pahlman, and H. Mahteme, “Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis,” Annals of Surgical Oncology, vol. 15, no. 3, pp. 745–753, 2008.
[8]
M. Vaira, T. Cioppa, G. De Marco et al., “Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience,” In Vivo, vol. 23, no. 4, pp. 639–644, 2009.
[9]
B. Moran, D. Baratti, T. D. Yan, S. Kusamura, and M. Deraco, “Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei),” Journal of Surgical Oncology, vol. 98, no. 4, pp. 277–282, 2008.
[10]
J. Bryant, A. J. Clegg, M. K. Sidhu, H. Brodin, P. Royle, and P. Davidson, “Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei,” Health Technology Assessment, vol. 8, no. 7, pp. 1–54, 2004.
[11]
T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker, “A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei,” Annals of Surgical Oncology, vol. 14, no. 2, pp. 484–492, 2007.
[12]
H. Yan, S. R. Pestieau, B. M. Shmookler, and P. H. Sugarbaker, “Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation,” Modern Pathology, vol. 14, no. 3, pp. 164–171, 2001.
[13]
P. H. Sugarbaker, “Peritonectomy procedures,” Annals of Surgery, vol. 221, no. 1, pp. 29–42, 1995.
[14]
R. P. McQuellon, B. W. Loggie, R. A. Fleming, G. B. Russell, A. B. Lehman, and T. D. Rambo, “Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis,” European Journal of Surgical Oncology, vol. 27, no. 1, pp. 65–73, 2001.
[15]
R. P. McQuellon, B. W. Loggie, A. B. Lehman et al., “Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis,” Annals of Surgical Oncology, vol. 10, no. 2, pp. 155–162, 2003.
[16]
U. Schmidt, M. H. Dahlke, J. Klempnauer, H. J. Schlitt, and P. Piso, “Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,” European Journal of Surgical Oncology, vol. 31, no. 1, pp. 53–58, 2005.
[17]
P. Piso, G. Glockzin, P. Von Breitenbuch et al., “Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies,” Journal of Surgical Oncology, vol. 100, no. 4, pp. 317–320, 2009.
[18]
A. R. Hill, R. P. McQuellon, G. B. Russell, P. Shen, J. H. Stewart IV, and E. A. Levine, “Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin,” Annals of Surgical Oncology, vol. 18, no. 13, pp. 3673–3679, 2011.
[19]
T. M. Tuttle, Y. Zhang, E. Greeno, and A. Knutsen, “Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy,” Annals of Surgical Oncology, vol. 13, no. 12, pp. 1627–1632, 2006.
[20]
P. Jess, L. H. Iversen, M. B. Nielsen, F. Hansen, S. Laurberg, and P. C. Rasmussen, “Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study,” Diseases of the Colon and Rectum, vol. 51, no. 6, pp. 868–874, 2008.
[21]
O. Glehen, D. Osinsky, E. Cotte et al., “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures,” Annals of Surgical Oncology, vol. 10, no. 8, pp. 863–869, 2003.
[22]
S. Kusamura, R. Younan, D. Baratti et al., “Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique,” Cancer, vol. 106, no. 5, pp. 1144–1153, 2006.
[23]
J. Hansson, W. Graf, L. P？hlman, P. Nygren, and H. Mahteme, “Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy,” European Journal of Surgical Oncology, vol. 35, no. 2, pp. 202–208, 2009.
[24]
H. Youssef, C. Newman, K. Chandrakumaran, F. Mohamed, T. D. Cecil, and B. J. Moran, “Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin,” Diseases of the Colon and Rectum, vol. 54, no. 3, pp. 293–299, 2011.
[25]
A. G. Kerscher, J. Mallalieu, A. Pitroff, F. Kerscher, and J. Esquivel, “Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital,” World Journal of Surgery, vol. 34, no. 1, pp. 62–69, 2010.
[26]
S. Alves, F. Mohamed, G. Yadegarfar, H. Youssef, and B. J. Moran, “Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei,” European Journal of Surgical Oncology, vol. 36, no. 12, pp. 1156–1161, 2010.
[27]
P. H. Sugarbaker, A. Casado-Adam, R. Alderman, O. A. Stuart, and D. Chang, “Gastorintestinal complications in 147 Consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy,” International Journal of Surgical Oncology, vol. 2011, Article ID 468698, 10 pages, 2011.
[28]
T. C. Chua, T. D. Yan, A. Saxena, and D. L. Morris, “Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality,” Annals of Surgery, vol. 249, no. 6, pp. 900–907, 2009.
